The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma

Cancer

Volumn 103, Issue 7, 2005, Pages 1397-1401

  Eitan, Ram ^a   Levine, Douglas A ^a   Abu Rustum, Nadeem ^a   Sonoda, Yukio ^a   Huh, Jae N ^a   Franklin, Corinna C ^a   Stevens, Tobey A ^a   Barakat, Richard R ^a   Chi, Dennis S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Optimal debulking; Ovarian carcinoma; Pleural effusion; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM;

ADULT; AGED; ASCITES; CANCER RECURRENCE; CANCER SURVIVAL; CYTOLOGY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 15744406047     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20920     Document Type: Review

References (21)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. [No authors listed.] FIGO annual report on the results of treatment in gynecologic cancer. J Epidemiol Biostat. 1998; 3:76.
3. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. J Epidemiol Biostat. 2001;6:107-138.
4. Penson RT, Skates SJ, Fuller AJ Jr., Seiden MV. Clinical course of Stage IV epithelial ovarian cancer. J Clin Oncol. 1999;17:3361-3362.
5. Bonnefoi H, A'Hern RP, Fisher C, et al. Natural history of Stage IV epithelial ovarian cancer. J Clin Oncol. 1999;17:767-775.
6. Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery [review]. Gynecol Oncol. 1994;55(3 Pt 2):S91-S96.
7. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-1259.
8. Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol. 2001;82:532-537.
9. Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol. 1997;64:9-12.
10. Liu PC, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC. Effect of surgical debulking on survival in Stage IV ovarian cancer. Gynecol Oncol. 1997;64:4-8.
11. Munkarah AR, Hallum AV III, Morris M, et al. Prognostic significance of residual disease in patients with Stage IV epithelial ovarian cancer. Gynecol Oncol. 1997;64:13-17.
12. Bristow RE, Montz F, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in Stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278-287.
13. Naik R, Nordin A, Cross PA, Hemming D, de Barros Lopes A, Monaghan JM. Optimal cytoreductive surgery is an independent prognostic indicator in Stage IV epithelial ovarian cancer with hepatic metastases. Gynecol Oncol. 2000;78:171-175.
14. International Federation of Gynecology and Obstetrics (FIGO) Cancer Committee. Staging announcement. Gynecol Oncol. 1986;25:383-385.
15. Marsden DE, Friedlander M, Hacker NF. Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol. 2000;19:11-19.
16. Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for Stage IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal carcinoma: a change in surgical approach. Gynecol Oncol. 2004;94:650-654.
17. Chi DS, Abu-Rustum NR, Sonoda Y, et al. The benefit of video-assisted thoracoscopic surgery (VATS) prior to planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions. Gynecol Oncol. 2004;94:307-311.
18. Eisenkop SM. Thoracoscopy for the management of advanced epithelial ovarian cancer - a preliminary report. Gynecol Oncol. 2002;84:315-320.
19. Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer. 2001;92:2585-2591.
20. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy of primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol. 1998;71: 431-436.
21. Schwartz PE, Thomas JR, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol. 1999;72:93-99.